nodes	percent_of_prediction	percent_of_DWPC	metapath
Topiramate—CYP3A4—bone cancer	0.58	1	CbGaD
Topiramate—GRIA4—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00706	0.0755	CbGpPWpGaD
Topiramate—GRIA3—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00513	0.0549	CbGpPWpGaD
Topiramate—CA9—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.00392	0.042	CbGpPWpGaD
Topiramate—SCN5A—Cardiac Progenitor Differentiation—T—bone cancer	0.00329	0.0352	CbGpPWpGaD
Topiramate—GRIA1—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00307	0.0329	CbGpPWpGaD
Topiramate—GRIA2—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00215	0.023	CbGpPWpGaD
Topiramate—GRIA4—Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity—MDM2—bone cancer	0.002	0.0214	CbGpPWpGaD
Topiramate—GRIA4—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.00186	0.0199	CbGpPWpGaD
Topiramate—SCN5A—SIDS Susceptibility Pathways—FEV—bone cancer	0.00163	0.0174	CbGpPWpGaD
Topiramate—GRIA3—Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity—MDM2—bone cancer	0.00145	0.0155	CbGpPWpGaD
Topiramate—GRIA1—Mecp2 and Associated Rett Syndrome—EZH2—bone cancer	0.00143	0.0153	CbGpPWpGaD
Topiramate—GRIA3—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.00135	0.0144	CbGpPWpGaD
Topiramate—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00117	0.0125	CbGpPWpGaD
Topiramate—GRIA3—BDNF signaling pathway—EIF2S1—bone cancer	0.00114	0.0122	CbGpPWpGaD
Topiramate—GABRA1—SIDS Susceptibility Pathways—FEV—bone cancer	0.00107	0.0115	CbGpPWpGaD
Topiramate—GRIK5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000879	0.0094	CbGpPWpGaD
Topiramate—GRIK4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000879	0.0094	CbGpPWpGaD
Topiramate—GRIA1—Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity—MDM2—bone cancer	0.000869	0.0093	CbGpPWpGaD
Topiramate—GRIK3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000817	0.00874	CbGpPWpGaD
Topiramate—GRIK1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000817	0.00874	CbGpPWpGaD
Topiramate—GRIA1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.000808	0.00864	CbGpPWpGaD
Topiramate—GABRB2—Orphan transporters—TUBB4B—bone cancer	0.000771	0.00825	CbGpPWpGaD
Topiramate—GRIK5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000736	0.00788	CbGpPWpGaD
Topiramate—GRIK4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000736	0.00788	CbGpPWpGaD
Topiramate—GABRG2—Orphan transporters—TUBB4B—bone cancer	0.000705	0.00755	CbGpPWpGaD
Topiramate—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000703	0.00752	CbGpPWpGaD
Topiramate—GRIA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000695	0.00743	CbGpPWpGaD
Topiramate—GRIK1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000685	0.00732	CbGpPWpGaD
Topiramate—GRIK3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000685	0.00732	CbGpPWpGaD
Topiramate—GRIA1—BDNF signaling pathway—EIF2S1—bone cancer	0.000681	0.00729	CbGpPWpGaD
Topiramate—GABRB2—Orphan transporters—TUBB2A—bone cancer	0.000666	0.00712	CbGpPWpGaD
Topiramate—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000662	0.00708	CbGpPWpGaD
Topiramate—GRIK4—Transmission across Chemical Synapses—BRAF—bone cancer	0.000661	0.00707	CbGpPWpGaD
Topiramate—GRIK5—Transmission across Chemical Synapses—BRAF—bone cancer	0.000661	0.00707	CbGpPWpGaD
Topiramate—GABRA1—Orphan transporters—TUBB4B—bone cancer	0.000617	0.0066	CbGpPWpGaD
Topiramate—GRIK1—Transmission across Chemical Synapses—BRAF—bone cancer	0.000614	0.00657	CbGpPWpGaD
Topiramate—GRIK3—Transmission across Chemical Synapses—BRAF—bone cancer	0.000614	0.00657	CbGpPWpGaD
Topiramate—GABRG2—Orphan transporters—TUBB2A—bone cancer	0.000609	0.00652	CbGpPWpGaD
Topiramate—GRIA2—Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity—MDM2—bone cancer	0.000608	0.0065	CbGpPWpGaD
Topiramate—GRIA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000582	0.00623	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—BMI1—bone cancer	0.000578	0.00618	CbGpPWpGaD
Topiramate—GRIA2—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.000565	0.00604	CbGpPWpGaD
Topiramate—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000564	0.00604	CbGpPWpGaD
Topiramate—GRIK4—Transmission across Chemical Synapses—MDM2—bone cancer	0.000554	0.00592	CbGpPWpGaD
Topiramate—GRIK5—Transmission across Chemical Synapses—MDM2—bone cancer	0.000554	0.00592	CbGpPWpGaD
Topiramate—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000543	0.00581	CbGpPWpGaD
Topiramate—GABRA1—Orphan transporters—TUBB2A—bone cancer	0.000532	0.00569	CbGpPWpGaD
Topiramate—GRIA4—Transmission across Chemical Synapses—BRAF—bone cancer	0.000522	0.00559	CbGpPWpGaD
Topiramate—GRIK1—Transmission across Chemical Synapses—MDM2—bone cancer	0.000515	0.00551	CbGpPWpGaD
Topiramate—GRIK3—Transmission across Chemical Synapses—MDM2—bone cancer	0.000515	0.00551	CbGpPWpGaD
Topiramate—GRIK5—Neuronal System—BRAF—bone cancer	0.000506	0.00542	CbGpPWpGaD
Topiramate—GRIK4—Neuronal System—BRAF—bone cancer	0.000506	0.00542	CbGpPWpGaD
Topiramate—GRIA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000505	0.0054	CbGpPWpGaD
Topiramate—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000503	0.00538	CbGpPWpGaD
Topiramate—GRIA2—BDNF signaling pathway—EIF2S1—bone cancer	0.000477	0.0051	CbGpPWpGaD
Topiramate—GRIK1—Neuronal System—BRAF—bone cancer	0.000471	0.00504	CbGpPWpGaD
Topiramate—GRIK3—Neuronal System—BRAF—bone cancer	0.000471	0.00504	CbGpPWpGaD
Topiramate—SCN5A—Cardiac Progenitor Differentiation—KIT—bone cancer	0.000446	0.00477	CbGpPWpGaD
Topiramate—GRIA4—Transmission across Chemical Synapses—MDM2—bone cancer	0.000438	0.00468	CbGpPWpGaD
Topiramate—CA1—C-MYB transcription factor network—KIT—bone cancer	0.000425	0.00454	CbGpPWpGaD
Topiramate—GRIK5—Neuronal System—MDM2—bone cancer	0.000424	0.00454	CbGpPWpGaD
Topiramate—GRIK4—Neuronal System—MDM2—bone cancer	0.000424	0.00454	CbGpPWpGaD
Topiramate—GRIA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000423	0.00453	CbGpPWpGaD
Topiramate—GRIA1—Amyotrophic lateral sclerosis (ALS)—TP53—bone cancer	0.000413	0.00442	CbGpPWpGaD
Topiramate—GRIA4—Neuronal System—BRAF—bone cancer	0.0004	0.00428	CbGpPWpGaD
Topiramate—GRIK3—Neuronal System—MDM2—bone cancer	0.000394	0.00422	CbGpPWpGaD
Topiramate—GRIK1—Neuronal System—MDM2—bone cancer	0.000394	0.00422	CbGpPWpGaD
Topiramate—CA6—Metabolism—NDUFA12—bone cancer	0.000388	0.00415	CbGpPWpGaD
Topiramate—CA5A—Metabolism—NDUFA12—bone cancer	0.000388	0.00415	CbGpPWpGaD
Topiramate—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000387	0.00415	CbGpPWpGaD
Topiramate—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00038	0.00406	CbGpPWpGaD
Topiramate—GRIA3—Transmission across Chemical Synapses—BRAF—bone cancer	0.000379	0.00406	CbGpPWpGaD
Topiramate—CA5B—Metabolism—NDUFA12—bone cancer	0.000362	0.00387	CbGpPWpGaD
Topiramate—CA7—Metabolism—NDUFA12—bone cancer	0.000362	0.00387	CbGpPWpGaD
Topiramate—GRIA3—BDNF signaling pathway—JUN—bone cancer	0.000359	0.00385	CbGpPWpGaD
Topiramate—GRIA4—Neuronal System—MDM2—bone cancer	0.000335	0.00359	CbGpPWpGaD
Topiramate—CA12—Metabolism—NDUFA12—bone cancer	0.000335	0.00359	CbGpPWpGaD
Topiramate—CA1—C-MYB transcription factor network—PTGS2—bone cancer	0.000322	0.00345	CbGpPWpGaD
Topiramate—CA6—Metabolism—NT5C3A—bone cancer	0.000321	0.00344	CbGpPWpGaD
Topiramate—CA5A—Metabolism—NT5C3A—bone cancer	0.000321	0.00344	CbGpPWpGaD
Topiramate—GRIA3—Transmission across Chemical Synapses—MDM2—bone cancer	0.000318	0.0034	CbGpPWpGaD
Topiramate—CA9—HIF-1-alpha transcription factor network—JUN—bone cancer	0.00031	0.00332	CbGpPWpGaD
Topiramate—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000303	0.00324	CbGpPWpGaD
Topiramate—GRIA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000302	0.00324	CbGpPWpGaD
Topiramate—CA5B—Metabolism—NT5C3A—bone cancer	0.0003	0.00321	CbGpPWpGaD
Topiramate—CA7—Metabolism—NT5C3A—bone cancer	0.0003	0.00321	CbGpPWpGaD
Topiramate—GRIA3—Neuronal System—BRAF—bone cancer	0.000291	0.00311	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—EZH2—bone cancer	0.000281	0.00301	CbGpPWpGaD
Topiramate—CA12—Metabolism—NT5C3A—bone cancer	0.000278	0.00297	CbGpPWpGaD
Topiramate—GRIK2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000277	0.00296	CbGpPWpGaD
Topiramate—CA4—Metabolism—NDUFA12—bone cancer	0.000267	0.00286	CbGpPWpGaD
Topiramate—CA2—Metabolism—NDUFA12—bone cancer	0.000256	0.00274	CbGpPWpGaD
Topiramate—GRIA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000253	0.00271	CbGpPWpGaD
Topiramate—Renal failure—Doxorubicin—bone cancer	0.000251	0.00077	CcSEcCtD
Topiramate—Erythema multiforme—Methotrexate—bone cancer	0.000251	0.000768	CcSEcCtD
Topiramate—Neuropathy peripheral—Doxorubicin—bone cancer	0.000251	0.000768	CcSEcCtD
Topiramate—Haemoglobin—Epirubicin—bone cancer	0.000249	0.000764	CcSEcCtD
Topiramate—Stomatitis—Doxorubicin—bone cancer	0.000249	0.000764	CcSEcCtD
Topiramate—Rhinitis—Epirubicin—bone cancer	0.000249	0.000762	CcSEcCtD
Topiramate—Conjunctivitis—Doxorubicin—bone cancer	0.000248	0.000762	CcSEcCtD
Topiramate—Urinary tract infection—Doxorubicin—bone cancer	0.000248	0.000762	CcSEcCtD
Topiramate—Hepatitis—Epirubicin—bone cancer	0.000248	0.00076	CcSEcCtD
Topiramate—Haemorrhage—Epirubicin—bone cancer	0.000248	0.00076	CcSEcCtD
Topiramate—Eye disorder—Methotrexate—bone cancer	0.000248	0.000759	CcSEcCtD
Topiramate—Tinnitus—Methotrexate—bone cancer	0.000247	0.000757	CcSEcCtD
Topiramate—Hypoaesthesia—Epirubicin—bone cancer	0.000247	0.000756	CcSEcCtD
Topiramate—Asthenia—Cisplatin—bone cancer	0.000246	0.000755	CcSEcCtD
Topiramate—Pharyngitis—Epirubicin—bone cancer	0.000246	0.000754	CcSEcCtD
Topiramate—Cardiac disorder—Methotrexate—bone cancer	0.000246	0.000754	CcSEcCtD
Topiramate—CA1—Metabolism—NDUFA12—bone cancer	0.000246	0.00263	CbGpPWpGaD
Topiramate—Urinary tract disorder—Epirubicin—bone cancer	0.000245	0.000751	CcSEcCtD
Topiramate—Oedema peripheral—Epirubicin—bone cancer	0.000244	0.000749	CcSEcCtD
Topiramate—Haematuria—Doxorubicin—bone cancer	0.000244	0.000747	CcSEcCtD
Topiramate—Connective tissue disorder—Epirubicin—bone cancer	0.000244	0.000747	CcSEcCtD
Topiramate—GRIA3—Neuronal System—MDM2—bone cancer	0.000244	0.00261	CbGpPWpGaD
Topiramate—Urethral disorder—Epirubicin—bone cancer	0.000243	0.000745	CcSEcCtD
Topiramate—Epistaxis—Doxorubicin—bone cancer	0.000241	0.000739	CcSEcCtD
Topiramate—Angiopathy—Methotrexate—bone cancer	0.00024	0.000737	CcSEcCtD
Topiramate—Sinusitis—Doxorubicin—bone cancer	0.00024	0.000735	CcSEcCtD
Topiramate—Immune system disorder—Methotrexate—bone cancer	0.000239	0.000734	CcSEcCtD
Topiramate—Visual impairment—Epirubicin—bone cancer	0.000239	0.000733	CcSEcCtD
Topiramate—Mediastinal disorder—Methotrexate—bone cancer	0.000239	0.000732	CcSEcCtD
Topiramate—Agranulocytosis—Doxorubicin—bone cancer	0.000239	0.000731	CcSEcCtD
Topiramate—Chills—Methotrexate—bone cancer	0.000238	0.000729	CcSEcCtD
Topiramate—Diarrhoea—Cisplatin—bone cancer	0.000235	0.00072	CcSEcCtD
Topiramate—Erythema multiforme—Epirubicin—bone cancer	0.000234	0.000719	CcSEcCtD
Topiramate—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000234	0.00251	CbGpPWpGaD
Topiramate—Alopecia—Methotrexate—bone cancer	0.000234	0.000718	CcSEcCtD
Topiramate—Bradycardia—Doxorubicin—bone cancer	0.000234	0.000716	CcSEcCtD
Topiramate—Mental disorder—Methotrexate—bone cancer	0.000232	0.000712	CcSEcCtD
Topiramate—GRIK2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000232	0.00248	CbGpPWpGaD
Topiramate—Eye disorder—Epirubicin—bone cancer	0.000232	0.00071	CcSEcCtD
Topiramate—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000231	0.00247	CbGpPWpGaD
Topiramate—Tinnitus—Epirubicin—bone cancer	0.000231	0.000709	CcSEcCtD
Topiramate—Malnutrition—Methotrexate—bone cancer	0.000231	0.000707	CcSEcCtD
Topiramate—Erythema—Methotrexate—bone cancer	0.000231	0.000707	CcSEcCtD
Topiramate—Haemoglobin—Doxorubicin—bone cancer	0.000231	0.000707	CcSEcCtD
Topiramate—Flushing—Epirubicin—bone cancer	0.00023	0.000706	CcSEcCtD
Topiramate—Cardiac disorder—Epirubicin—bone cancer	0.00023	0.000706	CcSEcCtD
Topiramate—Rhinitis—Doxorubicin—bone cancer	0.00023	0.000705	CcSEcCtD
Topiramate—Haemorrhage—Doxorubicin—bone cancer	0.000229	0.000703	CcSEcCtD
Topiramate—Hepatitis—Doxorubicin—bone cancer	0.000229	0.000703	CcSEcCtD
Topiramate—Hypoaesthesia—Doxorubicin—bone cancer	0.000228	0.0007	CcSEcCtD
Topiramate—Pharyngitis—Doxorubicin—bone cancer	0.000228	0.000698	CcSEcCtD
Topiramate—GRIA1—Transmission across Chemical Synapses—BRAF—bone cancer	0.000227	0.00243	CbGpPWpGaD
Topiramate—Urinary tract disorder—Doxorubicin—bone cancer	0.000227	0.000695	CcSEcCtD
Topiramate—Oedema peripheral—Doxorubicin—bone cancer	0.000226	0.000693	CcSEcCtD
Topiramate—Dysgeusia—Methotrexate—bone cancer	0.000226	0.000692	CcSEcCtD
Topiramate—Connective tissue disorder—Doxorubicin—bone cancer	0.000225	0.000691	CcSEcCtD
Topiramate—Angiopathy—Epirubicin—bone cancer	0.000225	0.00069	CcSEcCtD
Topiramate—Urethral disorder—Doxorubicin—bone cancer	0.000225	0.00069	CcSEcCtD
Topiramate—Immune system disorder—Epirubicin—bone cancer	0.000224	0.000687	CcSEcCtD
Topiramate—Mediastinal disorder—Epirubicin—bone cancer	0.000223	0.000685	CcSEcCtD
Topiramate—Back pain—Methotrexate—bone cancer	0.000223	0.000684	CcSEcCtD
Topiramate—Chills—Epirubicin—bone cancer	0.000223	0.000682	CcSEcCtD
Topiramate—CA4—Metabolism—NT5C3A—bone cancer	0.000222	0.00237	CbGpPWpGaD
Topiramate—Visual impairment—Doxorubicin—bone cancer	0.000221	0.000678	CcSEcCtD
Topiramate—Alopecia—Epirubicin—bone cancer	0.000219	0.000672	CcSEcCtD
Topiramate—CA9—Cellular responses to stress—GSTP1—bone cancer	0.000219	0.00234	CbGpPWpGaD
Topiramate—Vomiting—Cisplatin—bone cancer	0.000218	0.000669	CcSEcCtD
Topiramate—Vision blurred—Methotrexate—bone cancer	0.000217	0.000666	CcSEcCtD
Topiramate—Mental disorder—Epirubicin—bone cancer	0.000217	0.000666	CcSEcCtD
Topiramate—Erythema multiforme—Doxorubicin—bone cancer	0.000217	0.000665	CcSEcCtD
Topiramate—Rash—Cisplatin—bone cancer	0.000216	0.000663	CcSEcCtD
Topiramate—Dermatitis—Cisplatin—bone cancer	0.000216	0.000663	CcSEcCtD
Topiramate—CA9—Metabolism—NDUFA12—bone cancer	0.000216	0.00231	CbGpPWpGaD
Topiramate—Malnutrition—Epirubicin—bone cancer	0.000216	0.000662	CcSEcCtD
Topiramate—Erythema—Epirubicin—bone cancer	0.000216	0.000662	CcSEcCtD
Topiramate—GRIA1—BDNF signaling pathway—JUN—bone cancer	0.000215	0.0023	CbGpPWpGaD
Topiramate—Eye disorder—Doxorubicin—bone cancer	0.000214	0.000657	CcSEcCtD
Topiramate—Ill-defined disorder—Methotrexate—bone cancer	0.000214	0.000656	CcSEcCtD
Topiramate—Tinnitus—Doxorubicin—bone cancer	0.000214	0.000656	CcSEcCtD
Topiramate—Anaemia—Methotrexate—bone cancer	0.000213	0.000654	CcSEcCtD
Topiramate—Flushing—Doxorubicin—bone cancer	0.000213	0.000653	CcSEcCtD
Topiramate—Cardiac disorder—Doxorubicin—bone cancer	0.000213	0.000653	CcSEcCtD
Topiramate—Flatulence—Epirubicin—bone cancer	0.000213	0.000652	CcSEcCtD
Topiramate—CA2—Metabolism—NT5C3A—bone cancer	0.000212	0.00227	CbGpPWpGaD
Topiramate—SCN1A—L1CAM interactions—EGFR—bone cancer	0.000212	0.00227	CbGpPWpGaD
Topiramate—Tension—Epirubicin—bone cancer	0.000212	0.000649	CcSEcCtD
Topiramate—GRIA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000212	0.00226	CbGpPWpGaD
Topiramate—Dysgeusia—Epirubicin—bone cancer	0.000211	0.000648	CcSEcCtD
Topiramate—Nervousness—Epirubicin—bone cancer	0.00021	0.000643	CcSEcCtD
Topiramate—Back pain—Epirubicin—bone cancer	0.000209	0.00064	CcSEcCtD
Topiramate—Angiopathy—Doxorubicin—bone cancer	0.000208	0.000638	CcSEcCtD
Topiramate—Malaise—Methotrexate—bone cancer	0.000208	0.000638	CcSEcCtD
Topiramate—GRIK2—Transmission across Chemical Synapses—BRAF—bone cancer	0.000208	0.00222	CbGpPWpGaD
Topiramate—Muscle spasms—Epirubicin—bone cancer	0.000208	0.000636	CcSEcCtD
Topiramate—Immune system disorder—Doxorubicin—bone cancer	0.000207	0.000635	CcSEcCtD
Topiramate—Vertigo—Methotrexate—bone cancer	0.000207	0.000635	CcSEcCtD
Topiramate—Mediastinal disorder—Doxorubicin—bone cancer	0.000207	0.000634	CcSEcCtD
Topiramate—Leukopenia—Methotrexate—bone cancer	0.000206	0.000633	CcSEcCtD
Topiramate—Chills—Doxorubicin—bone cancer	0.000206	0.000631	CcSEcCtD
Topiramate—Nausea—Cisplatin—bone cancer	0.000204	0.000625	CcSEcCtD
Topiramate—CA1—Metabolism—NT5C3A—bone cancer	0.000204	0.00218	CbGpPWpGaD
Topiramate—Vision blurred—Epirubicin—bone cancer	0.000203	0.000624	CcSEcCtD
Topiramate—Alopecia—Doxorubicin—bone cancer	0.000203	0.000622	CcSEcCtD
Topiramate—Cough—Methotrexate—bone cancer	0.000201	0.000617	CcSEcCtD
Topiramate—Mental disorder—Doxorubicin—bone cancer	0.000201	0.000616	CcSEcCtD
Topiramate—Ill-defined disorder—Epirubicin—bone cancer	0.0002	0.000614	CcSEcCtD
Topiramate—Convulsion—Methotrexate—bone cancer	0.0002	0.000613	CcSEcCtD
Topiramate—Erythema—Doxorubicin—bone cancer	0.0002	0.000612	CcSEcCtD
Topiramate—Malnutrition—Doxorubicin—bone cancer	0.0002	0.000612	CcSEcCtD
Topiramate—Anaemia—Epirubicin—bone cancer	0.0002	0.000612	CcSEcCtD
Topiramate—Agitation—Epirubicin—bone cancer	0.000198	0.000608	CcSEcCtD
Topiramate—Flatulence—Doxorubicin—bone cancer	0.000197	0.000603	CcSEcCtD
Topiramate—Chest pain—Methotrexate—bone cancer	0.000196	0.000602	CcSEcCtD
Topiramate—Myalgia—Methotrexate—bone cancer	0.000196	0.000602	CcSEcCtD
Topiramate—Arthralgia—Methotrexate—bone cancer	0.000196	0.000602	CcSEcCtD
Topiramate—Tension—Doxorubicin—bone cancer	0.000196	0.000601	CcSEcCtD
Topiramate—Dysgeusia—Doxorubicin—bone cancer	0.000196	0.0006	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000195	0.000598	CcSEcCtD
Topiramate—Malaise—Epirubicin—bone cancer	0.000195	0.000597	CcSEcCtD
Topiramate—Discomfort—Methotrexate—bone cancer	0.000194	0.000595	CcSEcCtD
Topiramate—Nervousness—Doxorubicin—bone cancer	0.000194	0.000595	CcSEcCtD
Topiramate—Vertigo—Epirubicin—bone cancer	0.000194	0.000595	CcSEcCtD
Topiramate—Syncope—Epirubicin—bone cancer	0.000194	0.000593	CcSEcCtD
Topiramate—Leukopenia—Epirubicin—bone cancer	0.000193	0.000592	CcSEcCtD
Topiramate—Back pain—Doxorubicin—bone cancer	0.000193	0.000592	CcSEcCtD
Topiramate—Muscle spasms—Doxorubicin—bone cancer	0.000192	0.000589	CcSEcCtD
Topiramate—Palpitations—Epirubicin—bone cancer	0.000191	0.000585	CcSEcCtD
Topiramate—GRIA1—Transmission across Chemical Synapses—MDM2—bone cancer	0.00019	0.00204	CbGpPWpGaD
Topiramate—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00019	0.00203	CbGpPWpGaD
Topiramate—Confusional state—Methotrexate—bone cancer	0.00019	0.000582	CcSEcCtD
Topiramate—Loss of consciousness—Epirubicin—bone cancer	0.00019	0.000582	CcSEcCtD
Topiramate—Cough—Epirubicin—bone cancer	0.000188	0.000577	CcSEcCtD
Topiramate—GABRB2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000188	0.00201	CbGpPWpGaD
Topiramate—Vision blurred—Doxorubicin—bone cancer	0.000188	0.000577	CcSEcCtD
Topiramate—Convulsion—Epirubicin—bone cancer	0.000187	0.000573	CcSEcCtD
Topiramate—Infection—Methotrexate—bone cancer	0.000187	0.000573	CcSEcCtD
Topiramate—Hypertension—Epirubicin—bone cancer	0.000186	0.000571	CcSEcCtD
Topiramate—Ill-defined disorder—Doxorubicin—bone cancer	0.000185	0.000568	CcSEcCtD
Topiramate—Nervous system disorder—Methotrexate—bone cancer	0.000185	0.000566	CcSEcCtD
Topiramate—Anaemia—Doxorubicin—bone cancer	0.000185	0.000566	CcSEcCtD
Topiramate—Thrombocytopenia—Methotrexate—bone cancer	0.000184	0.000565	CcSEcCtD
Topiramate—Myalgia—Epirubicin—bone cancer	0.000184	0.000563	CcSEcCtD
Topiramate—Arthralgia—Epirubicin—bone cancer	0.000184	0.000563	CcSEcCtD
Topiramate—Chest pain—Epirubicin—bone cancer	0.000184	0.000563	CcSEcCtD
Topiramate—Agitation—Doxorubicin—bone cancer	0.000184	0.000563	CcSEcCtD
Topiramate—Anxiety—Epirubicin—bone cancer	0.000183	0.000561	CcSEcCtD
Topiramate—Skin disorder—Methotrexate—bone cancer	0.000183	0.000561	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000183	0.00056	CcSEcCtD
Topiramate—Hyperhidrosis—Methotrexate—bone cancer	0.000182	0.000558	CcSEcCtD
Topiramate—Discomfort—Epirubicin—bone cancer	0.000182	0.000557	CcSEcCtD
Topiramate—Malaise—Doxorubicin—bone cancer	0.00018	0.000552	CcSEcCtD
Topiramate—Dry mouth—Epirubicin—bone cancer	0.00018	0.000551	CcSEcCtD
Topiramate—Vertigo—Doxorubicin—bone cancer	0.000179	0.00055	CcSEcCtD
Topiramate—Anorexia—Methotrexate—bone cancer	0.000179	0.00055	CcSEcCtD
Topiramate—Syncope—Doxorubicin—bone cancer	0.000179	0.000549	CcSEcCtD
Topiramate—CA9—Metabolism—NT5C3A—bone cancer	0.000179	0.00192	CbGpPWpGaD
Topiramate—Leukopenia—Doxorubicin—bone cancer	0.000179	0.000548	CcSEcCtD
Topiramate—Confusional state—Epirubicin—bone cancer	0.000178	0.000545	CcSEcCtD
Topiramate—GRIA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000177	0.0019	CbGpPWpGaD
Topiramate—Palpitations—Doxorubicin—bone cancer	0.000177	0.000541	CcSEcCtD
Topiramate—Oedema—Epirubicin—bone cancer	0.000176	0.00054	CcSEcCtD
Topiramate—Hypotension—Methotrexate—bone cancer	0.000176	0.000539	CcSEcCtD
Topiramate—Loss of consciousness—Doxorubicin—bone cancer	0.000176	0.000538	CcSEcCtD
Topiramate—Infection—Epirubicin—bone cancer	0.000175	0.000537	CcSEcCtD
Topiramate—Cough—Doxorubicin—bone cancer	0.000174	0.000534	CcSEcCtD
Topiramate—GRIK2—Transmission across Chemical Synapses—MDM2—bone cancer	0.000174	0.00186	CbGpPWpGaD
Topiramate—GRIA1—Neuronal System—BRAF—bone cancer	0.000174	0.00186	CbGpPWpGaD
Topiramate—Shock—Epirubicin—bone cancer	0.000173	0.000531	CcSEcCtD
Topiramate—Convulsion—Doxorubicin—bone cancer	0.000173	0.000531	CcSEcCtD
Topiramate—Nervous system disorder—Epirubicin—bone cancer	0.000173	0.00053	CcSEcCtD
Topiramate—Thrombocytopenia—Epirubicin—bone cancer	0.000172	0.000529	CcSEcCtD
Topiramate—Hypertension—Doxorubicin—bone cancer	0.000172	0.000529	CcSEcCtD
Topiramate—GABRG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000172	0.00184	CbGpPWpGaD
Topiramate—Tachycardia—Epirubicin—bone cancer	0.000172	0.000527	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000172	0.000526	CcSEcCtD
Topiramate—Skin disorder—Epirubicin—bone cancer	0.000171	0.000525	CcSEcCtD
Topiramate—Hyperhidrosis—Epirubicin—bone cancer	0.00017	0.000522	CcSEcCtD
Topiramate—Insomnia—Methotrexate—bone cancer	0.00017	0.000522	CcSEcCtD
Topiramate—Arthralgia—Doxorubicin—bone cancer	0.00017	0.000521	CcSEcCtD
Topiramate—Chest pain—Doxorubicin—bone cancer	0.00017	0.000521	CcSEcCtD
Topiramate—Myalgia—Doxorubicin—bone cancer	0.00017	0.000521	CcSEcCtD
Topiramate—Anxiety—Doxorubicin—bone cancer	0.000169	0.000519	CcSEcCtD
Topiramate—Paraesthesia—Methotrexate—bone cancer	0.000169	0.000518	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000169	0.000518	CcSEcCtD
Topiramate—Discomfort—Doxorubicin—bone cancer	0.000168	0.000515	CcSEcCtD
Topiramate—Anorexia—Epirubicin—bone cancer	0.000168	0.000515	CcSEcCtD
Topiramate—Dyspnoea—Methotrexate—bone cancer	0.000168	0.000515	CcSEcCtD
Topiramate—Somnolence—Methotrexate—bone cancer	0.000167	0.000513	CcSEcCtD
Topiramate—Dry mouth—Doxorubicin—bone cancer	0.000166	0.00051	CcSEcCtD
Topiramate—Dyspepsia—Methotrexate—bone cancer	0.000166	0.000508	CcSEcCtD
Topiramate—Hypotension—Epirubicin—bone cancer	0.000165	0.000505	CcSEcCtD
Topiramate—Confusional state—Doxorubicin—bone cancer	0.000164	0.000504	CcSEcCtD
Topiramate—Decreased appetite—Methotrexate—bone cancer	0.000164	0.000502	CcSEcCtD
Topiramate—Oedema—Doxorubicin—bone cancer	0.000163	0.0005	CcSEcCtD
Topiramate—GABRB2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000163	0.00174	CbGpPWpGaD
Topiramate—Gastrointestinal disorder—Methotrexate—bone cancer	0.000163	0.000498	CcSEcCtD
Topiramate—Fatigue—Methotrexate—bone cancer	0.000162	0.000498	CcSEcCtD
Topiramate—Infection—Doxorubicin—bone cancer	0.000162	0.000496	CcSEcCtD
Topiramate—Pain—Methotrexate—bone cancer	0.000161	0.000494	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000161	0.000492	CcSEcCtD
Topiramate—Shock—Doxorubicin—bone cancer	0.00016	0.000492	CcSEcCtD
Topiramate—Nervous system disorder—Doxorubicin—bone cancer	0.00016	0.00049	CcSEcCtD
Topiramate—Thrombocytopenia—Doxorubicin—bone cancer	0.00016	0.000489	CcSEcCtD
Topiramate—Insomnia—Epirubicin—bone cancer	0.000159	0.000488	CcSEcCtD
Topiramate—GRIK2—Neuronal System—BRAF—bone cancer	0.000159	0.0017	CbGpPWpGaD
Topiramate—Tachycardia—Doxorubicin—bone cancer	0.000159	0.000488	CcSEcCtD
Topiramate—GRIA2—Transmission across Chemical Synapses—BRAF—bone cancer	0.000159	0.0017	CbGpPWpGaD
Topiramate—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000159	0.0017	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—CDK4—bone cancer	0.000159	0.0017	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—MET—bone cancer	0.000158	0.00169	CbGpPWpGaD
Topiramate—Skin disorder—Doxorubicin—bone cancer	0.000158	0.000485	CcSEcCtD
Topiramate—Paraesthesia—Epirubicin—bone cancer	0.000158	0.000485	CcSEcCtD
Topiramate—Hyperhidrosis—Doxorubicin—bone cancer	0.000158	0.000483	CcSEcCtD
Topiramate—Dyspnoea—Epirubicin—bone cancer	0.000157	0.000482	CcSEcCtD
Topiramate—Somnolence—Epirubicin—bone cancer	0.000157	0.00048	CcSEcCtD
Topiramate—Anorexia—Doxorubicin—bone cancer	0.000155	0.000476	CcSEcCtD
Topiramate—Feeling abnormal—Methotrexate—bone cancer	0.000155	0.000476	CcSEcCtD
Topiramate—Dyspepsia—Epirubicin—bone cancer	0.000155	0.000475	CcSEcCtD
Topiramate—Gastrointestinal pain—Methotrexate—bone cancer	0.000154	0.000472	CcSEcCtD
Topiramate—Decreased appetite—Epirubicin—bone cancer	0.000153	0.000469	CcSEcCtD
Topiramate—Hypotension—Doxorubicin—bone cancer	0.000152	0.000467	CcSEcCtD
Topiramate—Gastrointestinal disorder—Epirubicin—bone cancer	0.000152	0.000466	CcSEcCtD
Topiramate—Fatigue—Epirubicin—bone cancer	0.000152	0.000466	CcSEcCtD
Topiramate—Constipation—Epirubicin—bone cancer	0.000151	0.000462	CcSEcCtD
Topiramate—Pain—Epirubicin—bone cancer	0.000151	0.000462	CcSEcCtD
Topiramate—GRIA2—BDNF signaling pathway—JUN—bone cancer	0.000151	0.00161	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000151	0.00161	CbGpPWpGaD
Topiramate—Urticaria—Methotrexate—bone cancer	0.00015	0.000458	CcSEcCtD
Topiramate—SCN5A—L1CAM interactions—EGFR—bone cancer	0.000149	0.0016	CbGpPWpGaD
Topiramate—Body temperature increased—Methotrexate—bone cancer	0.000149	0.000456	CcSEcCtD
Topiramate—Abdominal pain—Methotrexate—bone cancer	0.000149	0.000456	CcSEcCtD
Topiramate—GABRG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000149	0.00159	CbGpPWpGaD
Topiramate—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000149	0.000455	CcSEcCtD
Topiramate—Insomnia—Doxorubicin—bone cancer	0.000147	0.000452	CcSEcCtD
Topiramate—Paraesthesia—Doxorubicin—bone cancer	0.000146	0.000449	CcSEcCtD
Topiramate—GRIA1—Neuronal System—MDM2—bone cancer	0.000146	0.00156	CbGpPWpGaD
Topiramate—Dyspnoea—Doxorubicin—bone cancer	0.000145	0.000446	CcSEcCtD
Topiramate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000145	0.00155	CbGpPWpGaD
Topiramate—Feeling abnormal—Epirubicin—bone cancer	0.000145	0.000445	CcSEcCtD
Topiramate—Somnolence—Doxorubicin—bone cancer	0.000145	0.000444	CcSEcCtD
Topiramate—Gastrointestinal pain—Epirubicin—bone cancer	0.000144	0.000442	CcSEcCtD
Topiramate—Dyspepsia—Doxorubicin—bone cancer	0.000143	0.00044	CcSEcCtD
Topiramate—Decreased appetite—Doxorubicin—bone cancer	0.000142	0.000434	CcSEcCtD
Topiramate—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000141	0.000431	CcSEcCtD
Topiramate—CA6—Metabolism—ENO2—bone cancer	0.000141	0.00151	CbGpPWpGaD
Topiramate—CA5A—Metabolism—ENO2—bone cancer	0.000141	0.00151	CbGpPWpGaD
Topiramate—Fatigue—Doxorubicin—bone cancer	0.000141	0.000431	CcSEcCtD
Topiramate—Urticaria—Epirubicin—bone cancer	0.00014	0.000429	CcSEcCtD
Topiramate—Pain—Doxorubicin—bone cancer	0.000139	0.000427	CcSEcCtD
Topiramate—Constipation—Doxorubicin—bone cancer	0.000139	0.000427	CcSEcCtD
Topiramate—Abdominal pain—Epirubicin—bone cancer	0.000139	0.000427	CcSEcCtD
Topiramate—Body temperature increased—Epirubicin—bone cancer	0.000139	0.000427	CcSEcCtD
Topiramate—Hypersensitivity—Methotrexate—bone cancer	0.000139	0.000425	CcSEcCtD
Topiramate—CA9—Cellular responses to stress—RB1—bone cancer	0.000138	0.00148	CbGpPWpGaD
Topiramate—Asthenia—Methotrexate—bone cancer	0.000135	0.000414	CcSEcCtD
Topiramate—Feeling abnormal—Doxorubicin—bone cancer	0.000134	0.000412	CcSEcCtD
Topiramate—GRIK2—Neuronal System—MDM2—bone cancer	0.000133	0.00143	CbGpPWpGaD
Topiramate—Gastrointestinal pain—Doxorubicin—bone cancer	0.000133	0.000409	CcSEcCtD
Topiramate—GRIA2—Transmission across Chemical Synapses—MDM2—bone cancer	0.000133	0.00143	CbGpPWpGaD
Topiramate—Pruritus—Methotrexate—bone cancer	0.000133	0.000408	CcSEcCtD
Topiramate—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000133	0.00142	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—MMP2—bone cancer	0.000132	0.00141	CbGpPWpGaD
Topiramate—CA5B—Metabolism—ENO2—bone cancer	0.000131	0.00141	CbGpPWpGaD
Topiramate—CA7—Metabolism—ENO2—bone cancer	0.000131	0.00141	CbGpPWpGaD
Topiramate—CA6—Metabolism—DHFR—bone cancer	0.000131	0.0014	CbGpPWpGaD
Topiramate—CA5A—Metabolism—DHFR—bone cancer	0.000131	0.0014	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00013	0.00139	CbGpPWpGaD
Topiramate—Hypersensitivity—Epirubicin—bone cancer	0.00013	0.000398	CcSEcCtD
Topiramate—Urticaria—Doxorubicin—bone cancer	0.00013	0.000397	CcSEcCtD
Topiramate—Abdominal pain—Doxorubicin—bone cancer	0.000129	0.000395	CcSEcCtD
Topiramate—Body temperature increased—Doxorubicin—bone cancer	0.000129	0.000395	CcSEcCtD
Topiramate—Diarrhoea—Methotrexate—bone cancer	0.000129	0.000395	CcSEcCtD
Topiramate—SCN5A—SIDS Susceptibility Pathways—JUN—bone cancer	0.000129	0.00138	CbGpPWpGaD
Topiramate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000127	0.00136	CbGpPWpGaD
Topiramate—Asthenia—Epirubicin—bone cancer	0.000126	0.000388	CcSEcCtD
Topiramate—Pruritus—Epirubicin—bone cancer	0.000125	0.000382	CcSEcCtD
Topiramate—Dizziness—Methotrexate—bone cancer	0.000124	0.000382	CcSEcCtD
Topiramate—CA5A—Metabolism—GNA11—bone cancer	0.000122	0.00131	CbGpPWpGaD
Topiramate—CA6—Metabolism—GNA11—bone cancer	0.000122	0.00131	CbGpPWpGaD
Topiramate—CA5B—Metabolism—DHFR—bone cancer	0.000122	0.0013	CbGpPWpGaD
Topiramate—CA7—Metabolism—DHFR—bone cancer	0.000122	0.0013	CbGpPWpGaD
Topiramate—GRIA2—Neuronal System—BRAF—bone cancer	0.000122	0.0013	CbGpPWpGaD
Topiramate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000122	0.0013	CbGpPWpGaD
Topiramate—CA12—Metabolism—ENO2—bone cancer	0.000122	0.0013	CbGpPWpGaD
Topiramate—Diarrhoea—Epirubicin—bone cancer	0.000121	0.00037	CcSEcCtD
Topiramate—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.00012	0.00129	CbGpPWpGaD
Topiramate—Hypersensitivity—Doxorubicin—bone cancer	0.00012	0.000368	CcSEcCtD
Topiramate—Vomiting—Methotrexate—bone cancer	0.00012	0.000367	CcSEcCtD
Topiramate—GABRB2—Transmission across Chemical Synapses—BRAF—bone cancer	0.000119	0.00128	CbGpPWpGaD
Topiramate—Rash—Methotrexate—bone cancer	0.000119	0.000364	CcSEcCtD
Topiramate—Dermatitis—Methotrexate—bone cancer	0.000119	0.000364	CcSEcCtD
Topiramate—Headache—Methotrexate—bone cancer	0.000118	0.000362	CcSEcCtD
Topiramate—CA9—Cellular responses to stress—MDM2—bone cancer	0.000118	0.00126	CbGpPWpGaD
Topiramate—Asthenia—Doxorubicin—bone cancer	0.000117	0.000359	CcSEcCtD
Topiramate—Dizziness—Epirubicin—bone cancer	0.000117	0.000357	CcSEcCtD
Topiramate—Pruritus—Doxorubicin—bone cancer	0.000115	0.000354	CcSEcCtD
Topiramate—CA7—Metabolism—GNA11—bone cancer	0.000114	0.00122	CbGpPWpGaD
Topiramate—CA5B—Metabolism—GNA11—bone cancer	0.000114	0.00122	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—CDK4—bone cancer	0.000113	0.00121	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—MET—bone cancer	0.000113	0.00121	CbGpPWpGaD
Topiramate—CA12—Metabolism—DHFR—bone cancer	0.000113	0.00121	CbGpPWpGaD
Topiramate—Vomiting—Epirubicin—bone cancer	0.000112	0.000343	CcSEcCtD
Topiramate—Nausea—Methotrexate—bone cancer	0.000112	0.000343	CcSEcCtD
Topiramate—Diarrhoea—Doxorubicin—bone cancer	0.000112	0.000342	CcSEcCtD
Topiramate—SCN5A—Axon guidance—MET—bone cancer	0.000111	0.00119	CbGpPWpGaD
Topiramate—Rash—Epirubicin—bone cancer	0.000111	0.000341	CcSEcCtD
Topiramate—Dermatitis—Epirubicin—bone cancer	0.000111	0.00034	CcSEcCtD
Topiramate—CA6—Metabolism—CYP3A4—bone cancer	0.000111	0.00118	CbGpPWpGaD
Topiramate—CA5A—Metabolism—CYP3A4—bone cancer	0.000111	0.00118	CbGpPWpGaD
Topiramate—Headache—Epirubicin—bone cancer	0.00011	0.000338	CcSEcCtD
Topiramate—GABRG2—Transmission across Chemical Synapses—BRAF—bone cancer	0.000109	0.00117	CbGpPWpGaD
Topiramate—Dizziness—Doxorubicin—bone cancer	0.000108	0.00033	CcSEcCtD
Topiramate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000106	0.00114	CbGpPWpGaD
Topiramate—CA12—Metabolism—GNA11—bone cancer	0.000106	0.00113	CbGpPWpGaD
Topiramate—Nausea—Epirubicin—bone cancer	0.000105	0.000321	CcSEcCtD
Topiramate—Vomiting—Doxorubicin—bone cancer	0.000104	0.000318	CcSEcCtD
Topiramate—CA5B—Metabolism—CYP3A4—bone cancer	0.000103	0.0011	CbGpPWpGaD
Topiramate—CA7—Metabolism—CYP3A4—bone cancer	0.000103	0.0011	CbGpPWpGaD
Topiramate—Rash—Doxorubicin—bone cancer	0.000103	0.000315	CcSEcCtD
Topiramate—Dermatitis—Doxorubicin—bone cancer	0.000103	0.000315	CcSEcCtD
Topiramate—CA9—Cellular responses to stress—JUN—bone cancer	0.000102	0.00109	CbGpPWpGaD
Topiramate—Headache—Doxorubicin—bone cancer	0.000102	0.000313	CcSEcCtD
Topiramate—GRIA2—Neuronal System—MDM2—bone cancer	0.000102	0.00109	CbGpPWpGaD
Topiramate—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000101	0.00108	CbGpPWpGaD
Topiramate—GABRB2—Transmission across Chemical Synapses—MDM2—bone cancer	0.0001	0.00107	CbGpPWpGaD
Topiramate—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	9.95e-05	0.00106	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—MMP9—bone cancer	9.93e-05	0.00106	CbGpPWpGaD
Topiramate—CA4—Metabolism—ENO2—bone cancer	9.7e-05	0.00104	CbGpPWpGaD
Topiramate—Nausea—Doxorubicin—bone cancer	9.68e-05	0.000297	CcSEcCtD
Topiramate—CA12—Metabolism—CYP3A4—bone cancer	9.57e-05	0.00102	CbGpPWpGaD
Topiramate—GABRA1—Transmission across Chemical Synapses—BRAF—bone cancer	9.55e-05	0.00102	CbGpPWpGaD
Topiramate—CA5A—Metabolism—GSTP1—bone cancer	9.46e-05	0.00101	CbGpPWpGaD
Topiramate—CA6—Metabolism—GSTP1—bone cancer	9.46e-05	0.00101	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—MMP2—bone cancer	9.43e-05	0.00101	CbGpPWpGaD
Topiramate—CA2—Metabolism—ENO2—bone cancer	9.3e-05	0.000995	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—MMP2—bone cancer	9.29e-05	0.000994	CbGpPWpGaD
Topiramate—GABRG2—Transmission across Chemical Synapses—MDM2—bone cancer	9.15e-05	0.000979	CbGpPWpGaD
Topiramate—GABRB2—Neuronal System—BRAF—bone cancer	9.15e-05	0.000979	CbGpPWpGaD
Topiramate—CA4—Metabolism—DHFR—bone cancer	9e-05	0.000963	CbGpPWpGaD
Topiramate—CA1—Metabolism—ENO2—bone cancer	8.92e-05	0.000954	CbGpPWpGaD
Topiramate—CA5B—Metabolism—GSTP1—bone cancer	8.83e-05	0.000945	CbGpPWpGaD
Topiramate—CA7—Metabolism—GSTP1—bone cancer	8.83e-05	0.000945	CbGpPWpGaD
Topiramate—CA2—Metabolism—DHFR—bone cancer	8.63e-05	0.000923	CbGpPWpGaD
Topiramate—CYP2C19—Biological oxidations—GSTP1—bone cancer	8.63e-05	0.000923	CbGpPWpGaD
Topiramate—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	8.51e-05	0.000911	CbGpPWpGaD
Topiramate—GABRA1—SIDS Susceptibility Pathways—JUN—bone cancer	8.48e-05	0.000907	CbGpPWpGaD
Topiramate—CA4—Metabolism—GNA11—bone cancer	8.41e-05	0.0009	CbGpPWpGaD
Topiramate—GABRG2—Neuronal System—BRAF—bone cancer	8.37e-05	0.000895	CbGpPWpGaD
Topiramate—CA1—Metabolism—DHFR—bone cancer	8.28e-05	0.000885	CbGpPWpGaD
Topiramate—CA12—Metabolism—GSTP1—bone cancer	8.18e-05	0.000875	CbGpPWpGaD
Topiramate—CA2—Metabolism—GNA11—bone cancer	8.07e-05	0.000863	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—EGFR—bone cancer	8.02e-05	0.000858	CbGpPWpGaD
Topiramate—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	8.01e-05	0.000857	CbGpPWpGaD
Topiramate—GABRA1—Transmission across Chemical Synapses—MDM2—bone cancer	8e-05	0.000856	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—MET—bone cancer	7.94e-05	0.00085	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—CDK4—bone cancer	7.94e-05	0.00085	CbGpPWpGaD
Topiramate—CA9—Metabolism—ENO2—bone cancer	7.84e-05	0.000839	CbGpPWpGaD
Topiramate—CA1—Metabolism—GNA11—bone cancer	7.73e-05	0.000827	CbGpPWpGaD
Topiramate—GABRB2—Neuronal System—MDM2—bone cancer	7.67e-05	0.00082	CbGpPWpGaD
Topiramate—CA4—Metabolism—CYP3A4—bone cancer	7.63e-05	0.000816	CbGpPWpGaD
Topiramate—GABRA1—Neuronal System—BRAF—bone cancer	7.32e-05	0.000783	CbGpPWpGaD
Topiramate—CA2—Metabolism—CYP3A4—bone cancer	7.31e-05	0.000782	CbGpPWpGaD
Topiramate—CA9—Metabolism—DHFR—bone cancer	7.28e-05	0.000778	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—MMP9—bone cancer	7.08e-05	0.000758	CbGpPWpGaD
Topiramate—GABRG2—Neuronal System—MDM2—bone cancer	7.01e-05	0.00075	CbGpPWpGaD
Topiramate—CA1—Metabolism—CYP3A4—bone cancer	7.01e-05	0.00075	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—MMP9—bone cancer	6.98e-05	0.000747	CbGpPWpGaD
Topiramate—CA9—Metabolism—GNA11—bone cancer	6.8e-05	0.000727	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—TP53—bone cancer	6.75e-05	0.000722	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—MMP2—bone cancer	6.63e-05	0.000709	CbGpPWpGaD
Topiramate—CA4—Metabolism—GSTP1—bone cancer	6.52e-05	0.000698	CbGpPWpGaD
Topiramate—CA2—Metabolism—GSTP1—bone cancer	6.26e-05	0.000669	CbGpPWpGaD
Topiramate—CA9—Metabolism—CYP3A4—bone cancer	6.16e-05	0.00066	CbGpPWpGaD
Topiramate—GABRA1—Neuronal System—MDM2—bone cancer	6.13e-05	0.000656	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—NDUFA12—bone cancer	6.05e-05	0.000647	CbGpPWpGaD
Topiramate—CA1—Metabolism—GSTP1—bone cancer	6e-05	0.000642	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—EGFR—bone cancer	5.73e-05	0.000613	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—EGFR—bone cancer	5.64e-05	0.000603	CbGpPWpGaD
Topiramate—CA9—Metabolism—GSTP1—bone cancer	5.27e-05	0.000564	CbGpPWpGaD
Topiramate—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.19e-05	0.000555	CbGpPWpGaD
Topiramate—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.12e-05	0.000548	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—NT5C3A—bone cancer	5.01e-05	0.000536	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—MMP9—bone cancer	4.98e-05	0.000533	CbGpPWpGaD
Topiramate—CA5A—Metabolism—PTGS2—bone cancer	4.9e-05	0.000524	CbGpPWpGaD
Topiramate—CA6—Metabolism—PTGS2—bone cancer	4.9e-05	0.000524	CbGpPWpGaD
Topiramate—CA5B—Metabolism—PTGS2—bone cancer	4.58e-05	0.000489	CbGpPWpGaD
Topiramate—CA7—Metabolism—PTGS2—bone cancer	4.58e-05	0.000489	CbGpPWpGaD
Topiramate—CA12—Metabolism—PTGS2—bone cancer	4.24e-05	0.000453	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—EGFR—bone cancer	4.02e-05	0.000431	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—NDUFA12—bone cancer	3.64e-05	0.000389	CbGpPWpGaD
Topiramate—CA4—Metabolism—PTGS2—bone cancer	3.38e-05	0.000362	CbGpPWpGaD
Topiramate—CA2—Metabolism—PTGS2—bone cancer	3.24e-05	0.000347	CbGpPWpGaD
Topiramate—CA1—Metabolism—PTGS2—bone cancer	3.11e-05	0.000332	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—NT5C3A—bone cancer	3.01e-05	0.000322	CbGpPWpGaD
Topiramate—CA9—Metabolism—PTGS2—bone cancer	2.73e-05	0.000292	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—ENO2—bone cancer	2.2e-05	0.000235	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—DHFR—bone cancer	2.04e-05	0.000218	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—GNA11—bone cancer	1.9e-05	0.000204	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—CYP3A4—bone cancer	1.73e-05	0.000185	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.72e-05	0.000184	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—GSTP1—bone cancer	1.48e-05	0.000158	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—ENO2—bone cancer	1.32e-05	0.000141	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—DHFR—bone cancer	1.22e-05	0.000131	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—GNA11—bone cancer	1.14e-05	0.000122	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—GSTP1—bone cancer	8.88e-06	9.5e-05	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—PTGS2—bone cancer	7.65e-06	8.18e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—PTGS2—bone cancer	4.6e-06	4.92e-05	CbGpPWpGaD
